News

 

 

Funding: New Awards

New Awards

American Cancer Society has awarded NCCC an Institutional Research Grant (IRG) to support $450,000 direct costs absorbed from 1/1/2013 to 12/31/2015 for research approved by the local IRG. Dr. Mark Israel will serve as principal investigator.

Todd Miller, PhD
Member of the Molecular Therapeutics Research Program at Norris Cotton Cancer Center and Assistant Professor of Pharmacology and Toxicology at the Geisel School of Medicine at Dartmouth

On November 17 Dr. Miller will be awarded $50k from the Doctors’ Cancer Foundation. He will give a presentation at their fundraiser in Harrison, NY, where I will accept this award.
Mechanism: Management of Cancer Grant
Title: Circulating tumor DNA as a biomarker of disease burden and response to cytotoxic therapy

William North, PhD
Member of the Molecular Therapeutics Research Program at Norris Cotton Cancer Center and Professor of Physiology at the Geisel School of Medicine at Dartmouth

Woomera Therapeutics Inc. a small start-up company with Dr. Bill North as President recently was awarded an SBIR Phase 2 grant to develop an antibody treatment of small-cell lung cancer

Linda Titus, PhD
Member Cancer Epidemiology and Chemoprevention Research Program at Norris Cotton Cancer Center and Professor of Community and Family Medicine and of Pediatrics and of The Dartmouth Institute at the Geisel School of Medicine at Dartmouth

NCI, a contract supplement to conduct this study:  Hormones and DNA Methylation Patterns in DES-Exposed Women (Titus, PI)

Scott Williams, PhD
Member of the Cancer Epidemiology and Chemoprevention Research Program at the Norris Cotton Cancer Center and Professor of Genetics at the Geisel School of Medicine at Dartmouth

1R01 CA162433-01A1 (Pozzi)            08/01/2012-06/30/2017
NIH/NCI
The P450 Epoxygenases as Pro-Oncogenic Enzymes

1R03DK095097-01 (Villegas)    04/01/2012-03/31/2014 NIH/NIDDK   
Gene and environment interaction and insulin resistance

New Clinical Trials

Konstantin Dragnev
Associate Professor
Cancer Epidemiology and Chemoprevention

  • Eli Lilly, Co.
    A randomized, double-blind, Phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy

  • Department Funding
    Understanding risk of recurrence of melanoma at time of primary diagnosis

Kathleen Lyons
Research Assistant Professor
Cancer Control          

  • Department Funding
    A Phase I randomized controlled trial of a problem-solving occupational therapy intervention for older adult cancer survivors

J Marc Pipas
Associate Professor
Molecular Therapeutics

  • Bayer HealthCare Pharmaceuticals, Inc.
    An open-label Phase IIIb study of regorafenib in patients with metastatic Colorectal Cancer (CRC) who have progressed after standard therapy

James R. Rigas
Associate Professor
Molecular Therapeutics

  • Sanofi-Aventis
    Randomized Phase II study of cabazitaxel versus topotecan in small cell lung cancer patients with progressive disease during or after a first line platinum based chemotherapy